Chen Wei-Xian, Lou Ming, Cheng Lin, Qian Qi, Xu Ling-Yun, Sun Li, Zhu Yu-Lan, Dai Hong
Department of Breast Surgery, The Second Affiliated Changzhou People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China.
Department of Post-doctoral Working Station, The Second Affiliated Changzhou People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China.
Oncol Lett. 2019 Dec;18(6):6017-6025. doi: 10.3892/ol.2019.10949. Epub 2019 Oct 2.
GTPase activating proteins (RhoGAPs) serve significant roles in multiple aspects of tumor biology. Genes encoding RhoGAPs (), which switch off Rho-like GTPases, are responsible for breast cancer biogenesis. However, the identification of suitable and novel biomarkers for precision treatment and prognosis remains challenging. The present study aimed to evaluate the expression of ARHGAP family genes in breast cancer and investigate the survival data using the Oncomine, Kaplan-Meier Plotter, bcGenExMiner and cBioPortal online databases. The results demonstrated low expression of and and high expression of and in patients with breast cancer compared with that in healthy individuals. The survival analysis revealed that low expression levels of and were associated with poor relapse-free survival (RFS) and overall survival (OS), whereas high expression levels of and were associated with preferable RFS and OS. Metastatic relapse data demonstrated that higher expression of and were associated with better prognosis and increased expression of and exerted negative effects on patient prognosis. The overlapping genes and obtained from these bioinformatics analysis tools exhibited significant association with clinical parameters including age, the presence of estrogen receptor, progesterone receptor and epidermal growth factor receptor-2, Scarff-Bloom-Richardson grade and Nottingham prognostic index. In conclusion, bioinformatics analysis revealed that and , but not other ARHGAP family genes may be promising targets with prognostic value and biological function for precision treatment of breast cancer.
GTP酶激活蛋白（RhoGAPs）在肿瘤生物学的多个方面发挥着重要作用。编码RhoGAPs（关闭Rho样GTP酶）的基因与乳腺癌的发生有关。然而，识别适合的新型生物标志物用于精准治疗和预后评估仍然具有挑战性。本研究旨在评估ARHGAP家族基因在乳腺癌中的表达，并使用Oncomine、Kaplan-Meier Plotter、bcGenExMiner和cBioPortal在线数据库研究生存数据。结果表明，与健康个体相比，乳腺癌患者中[具体基因1]和[具体基因2]表达低，[具体基因3]和[具体基因4]表达高。生存分析显示，[具体基因1]和[具体基因2]低表达与无复发生存期（RFS）和总生存期（OS）差相关，而[具体基因3]和[具体基因4]高表达与较好的RFS和OS相关。转移复发数据表明，[具体基因3]和[具体基因4]高表达与较好的预后相关，[具体基因1]和[具体基因2]表达增加对患者预后有负面影响。从这些生物信息学分析工具获得的重叠基因[具体基因5]和[具体基因6]与包括年龄、雌激素受体、孕激素受体和表皮生长因子受体-2的存在、斯卡夫-布卢姆-理查森分级和诺丁汉预后指数等临床参数显著相关。总之，生物信息学分析显示，[具体基因5]和[具体基因6]而非其他ARHGAP家族基因可能是具有预后价值和生物学功能的有前景的靶点，用于乳腺癌的精准治疗。
